Neuroendocrine-type prostatic adenocarcinoma with microsatellite instability in a patient with Lynch syndrome

International Journal of Surgical Pathology

Volumn 18, Issue 6, 2010, Pages 550-553

  Wagner, David G ^a   Gatalica, Zoran ^b   Lynch, Henry T ^b   Kohl, Shane ^c   Johansson, Sonny L ^a   Lele, Subodh M ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^c Methodist Hospital   (United States)

Author keywords

carcinoma; Lynch; neuroendocrine; prostate

Indexed keywords

PROTEIN MSH2;

AGED; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CANCER GRADING; CANCER PATIENT; CARCINOMA IN SITU; CASE REPORT; FAMILIAL CANCER; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MALE; MICROSATELLITE INSTABILITY; MSH2 GENE; NEUROENDOCRINE TUMOR; ONCOGENE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CARCINOMA; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SMALL CELL CARCINOMA;

ADENOCARCINOMA; AGED, 80 AND OVER; CARCINOMA; CARCINOMA, NEUROENDOCRINE; CARCINOMA, SMALL CELL; HUMANS; IMMUNOHISTOCHEMISTRY; LYNCH SYNDROME II; MALE; MICROSATELLITE INSTABILITY; MUTS HOMOLOG 2 PROTEIN; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; URETERAL NEOPLASMS;

EID: 78649249282     PISSN: 10668969     EISSN: 19402465     Source Type: Journal    
DOI: 10.1177/1066896910379406     Document Type: Article

References (15)

1. Peltomaki P., Vasen H., Jass JR Hereditary nonpolyposis colorectal cancer. In: Hamilton SR, Aaltonen LA, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon, France: International Agency for Research on Cancer ; 2000: 126-129.
2. Vasen HF, Mecklin JP, Khan PM, Lynch HT The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum. 1991 ; 34: 424-425.
3. Vasen HF, Watson P., Mecklin JP, Lynch HT New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology. 1999 ; 116: 1453-1456.
4. Soravia C., van der Klift H., Brundler M., et al. Prostate cancer is part of the hereditary non-polyposis colorectal cancer (HNPCC) tumor spectrum. Am J Med Genet A. 2003 ; 121: 159-162.
5. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 ; 58: 5248-5257.
6. Wilson TM, Ewel A., Duguid JR, et al. Differential cellular expression of the human MSH2 repair enzyme in small and large intestine. Cancer Res. 1995 ; 55: 5146-5150.
7. Kolodner RD, Marsischky GT Eukaryotic DNA mismatch repair. Curr Opin Genet Dev. 1999 ; 9: 89-96.
8. Lynch HT, Smyrk T., Lynch J. An update of HNPCC (Lynch syndrome). Cancer Genet Cytogenet. 1997 ; 93: 84-99.
9. Vasen HF, Wijnen JT, Menko FH, et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology. 1996 ; 110: 1020-1027.
10. Scott RJ, McPhillips M., Meldrum CJ, et al. Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. Am J Hum Genet. 2001 ; 68: 118-127.
11. Fredriksson H., Ikonen T., Autio V., et al. Identification of germline MLH1 alterations in familial prostate cancer. Eur J Cancer. 2006 ; 42: 2802-2806.
12. Honchel R., Halling KC, Schaid DJ, Pittelkow M., Thibodeua SN Microsatellite instability in Muir-Torre syndrome. Cancer Res. 1994 ; 97: 159-163.
13. Crawford ED Epidemiology of prostate cancer. Urology. 2003 ; 62: 3-12.
14. Gayther SA, de Foy KA, Harrington P., et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators Cancer Res. 2000 ; 60: 4513-4518.
15. Gallagher D., Gaudet M., Pal P., et al. Germline BRCA mutations denote a clinicopathologic subset of prostate cancer. Clin Cancer Res. 2010 ; 16: 2115-2121.